Pharmaceuticals, Biotechnology and Life Sciences
– Initiation follows positive results from cohort 7 of phase 1b COSMIC-021 trial – – CONTACT-01 is the first of…
– Initiation follows positive results from cohort 7 of phase 1b COSMIC-021 trial – – CONTACT-01 is the first of…
– Initiation follows positive results from cohort 7 of phase 1b COSMIC-021 trial – – CONTACT-01 is the first of…
Phase 3 study of 30,000 subjects expected to begin in July 2020 at 100 μg dose level Manufacturing scale up…
Phase 3 study of 30,000 subjects expected to begin in July 2020 at 100 μg dose level Manufacturing scale up…
Phase 3 study of 30,000 subjects expected to begin in July 2020 at 100 μg dose level Manufacturing scale up…
Phase 3 study of 30,000 subjects expected to begin in July 2020 at 100 μg dose level Manufacturing scale up…
Phase 3 study of 30,000 subjects expected to begin in July 2020 at 100 μg dose level Manufacturing scale up…
PARIS–(BUSINESS WIRE)–Egle Therapeutics SAS, an emerging biotechnology company focused on developing first-in-class immunotherapies targeting immune suppressor regulatory T-cells for oncology…
PARIS–(BUSINESS WIRE)–Egle Therapeutics SAS, an emerging biotechnology company focused on developing first-in-class immunotherapies targeting immune suppressor regulatory T-cells for oncology…